DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-742/S-020

Merck & Co., Inc.
Attention: Peter Kusma
Manager, Worldwide Regulatory Affairs
UG2CD-48, POB 1000
North Wales, PA 19454-1099

Dear Mr. Kusma:

Please refer to your supplemental new drug application dated August 31, 2007, received August 31, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for STROMECTOL™ (ivermectin) Tablets, 3 mg and 6 mg.

This "Changes Being Effected" supplemental new drug application provides for the stability site transfer from the Haarlem Stability Unit to the European Stability Unit.

We completed our review of this supplemental new drug application. This supplement is approved.

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Robert Hummel, Regulatory Project Manager for Quality, at (301) 796-1981.

Sincerely,

{See appended electronic signature page}

Hasmukh B. Patel, Ph.D.
Branch Chief
Branch VIII, Division of Post-Marketing Evaluation
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Hasmukh Patel

2/26/2008 10:40:35 AM